Skip to primary navigation Skip to content
St. Paul Radiology logo
Skip to content
Skip to content

News and Events

Radiology is a broad and constantly evolving medical specialty. Find out about events we will be involved in, and check out the latest St. Paul Radiology news here.

SPR Now Offers SIR-Spheres

| News, Medicine

Treatment Extends Survival Time to Patients with Metastatic Liver Tumors

St. Paul Radiology is pleased to announce the availability of SIR-Spheres Microspheres1 at Regions Hospital. Manufactured by Sirtex for patients with metastatic liver cancer, SIR-Spheres microspheres are the only fully FDA-approved microspheres for colorectal cancer that has metastasized to the liver.

At least 60 percent2 of the nearly 150,000 Americans diagnosed with colorectal cancer every year will see their cancer spread to the liver, and most liver tumors cannot be surgically resected. Metastatic liver cancer is often fatal, with up to 90 percent of patients dying from liver failure. Microspheres therapy has emerged as a treatment option for patients with colorectal cancer that has spread to the liver.


SIR-Spheres Selectively Target Liver Tumors With Precision

SIR-Spheres microspheres are microscopic radioactive spheres that can be delivered by the millions directly to the tumor site. The microspheres contain the radioactive isotope yttrium-90, which delivers beta radiation to the tumor. The microspheres selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy while sparing healthy tissue.

SIR-Spheres microspheres are a powerful weapon against one of the deadliest forms of cancer. In the past, we were able to offer patients few, if any, targeted treatment options. SIR-Spheres microspheres have been proven to extend patient survival and, just as importantly, the treatment allows patients to maintain a good quality of life.

SIR-Spheres microspheres are indicated for treatment of unresectable metastatic colorectal cancer that has spread to the liver. Ongoing research and peer reviewed published papers in the literature suggest that yttrium-90 microspheres may also be effective in treating other forms of liver tumors. These include tumors from hepatocellular carcinoma as well as liver metastases from other primary sources. Treatment for these tumor types is investigational and is not approved under the current SIR-Spheres microspheres FDA approval.


1SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).

2SH, Murray T, Bolden S, et al. Cancer Statistics, 1999. CA Cancer J Clin 1999; 49:8 – 31, 31.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Statamic Debug Panel

You’re seeing this panel because _display_debug_panel is true in your site settings.

Page rendered in: 2.289665s

values: 
  template: entries/entry
  layout: default
  statamic_version: 1.11.2
  php_version: 5.6.30
  theme: spr
  environment: (none)
  memory_used: 22.00 MB

counts: 
  files: 
    opened: 129
    written: 3

  parses: 
    yaml: 19
    markdown: 107
    smartypants: 114
    statamic_tmpl: 371
    condition_statements: 1
    conditions: 1

  modifiers: 
    deslugify: 1
    title: 9
    format: 29
    list: 1
    slugify: 20
    urldummy: 1
    replace: 2
    length: 14
    upper: 34

  plugins: 
    get_content: 8
    theme: 7
    transform: 31
    entries: 2
    taxonomy: 2
    globals: 2
    relate: 33
    is_active: 162
    nav: 18
    pages: 2

  partials: 
    entries/header: 1
    entries/sidebar: 1
    navs/quick_links: 1
    header: 1
    navs/primary: 2
    navs/footer: 1

  folders: 
    created: 31
activity: 
  debug (74ms): 
    0.0466s: timing
    0.0265s: counting
    0.0006s: timelining

  parsing (662ms): 
    0.3843s: statamic_tmpl
    0.1321s: smartypants
    0.1122s: markdown
    0.0329s: yaml
    0.0001s: conditions

  config (4ms): 
    0.0040s: finding

  caching (998ms): 
    0.9897s: content
    0.0078s: settings
    0.0006s: member

  hooks (10ms): 
    0.0082s: running
    0.0017s: finding

  math (4ms): 
    0.0036s: hashing

  content (478ms): 
    0.2333s: preparing
    0.1778s: getting
    0.0599s: supplementing
    0.0062s: filtering
    0.0008s: sorting
    0.0002s: limiting

  modifiers (69ms): 
    0.0207s: upper
    0.0148s: format
    0.0139s: slugify
    0.0077s: length
    0.0046s: title
    0.0044s: replace
    0.0010s: urldummy
    0.0009s: deslugify
    0.0006s: list

  plugins (2948ms): 
    0.8361s: theme:partial
    0.5265s: get_content:index
    0.4837s: relate:page
    0.3783s: relate:columns
    0.3357s: nav:index
    0.2068s: entries:listing
    0.1059s: is_active:index
    0.0424s: transform:index
    0.0203s: pages:listing
    0.0091s: taxonomy:listing
    0.0021s: globals:logo
    0.0002s: var:index
    0.0001s: site_url:index
    0.0001s: facebook_url:index
    0.0001s: youtube_url:index
    0.0001s: twitter_username:index
    0.0001s: admin_address:index
    0.0001s: body_class:index

  partials (832ms): 
    0.5444s: navs/primary
    0.2346s: entries/sidebar
    0.0298s: navs/footer
    0.0135s: header
    0.0064s: navs/quick_links
    0.0034s: entries/header
timeline: 
  0.0000s: --------- start
  0.0211s:    ~21ms  autoloaders ready
  0.0652s:    ~44ms  bootstrapped
  0.0694s:     ~4ms  app created
  0.0698s:     ~0ms  app configured
  0.0701s:     ~0ms  localization ready
  0.0727s:     ~3ms  app defaults set
  1.3906s: ~1,318ms  caches updated
  1.3966s:     ~6ms  routes started
  1.4070s:    ~10ms  hooks initialized
  1.4071s:     ~0ms  segments determined
  1.4073s:     ~0ms  routes determined
  1.4288s:    ~21ms  content found
  1.4313s:     ~3ms  status determined
  1.4337s:     ~2ms  template picked
  1.4337s:     ~0ms  layout picked
  1.6825s:   ~249ms  template rendered
  2.2886s:   ~606ms  layout rendered
  2.2890s:     ~0ms  page ready
  2.2897s: --------- end